Long-term safety and efficacy of treating symptomatic, partial-thickness rotator cuff tears with fresh, uncultured, unmodified, autologous, adipose-derived regenerative cells isolated at the point of care: 40 months follow-up of a prospective, randomized, controlled, first-in-human clinical trial

Mark Lundeen, Jason L. Hurd, Matthew Hayes, Meredith Hayes, Tiffany R. Facile, John P. Furia, Nicola Maffulli, Christopher Alt, Eckhard U. Alt, Christoph Schmitz, David A. Pearce
doi: https://doi.org/10.1101/2022.12.14.22283447

Article usage

Article usage: December 2022 to August 2025

AbstractFullPdf
Dec 20223241146
Jan 2023132513
Feb 2023365851
Mar 2023102322
Apr 202336414
May 20232314
Jun 20232048
Jul 20231317
Aug 2023191216
Sep 202324611
Oct 20231245
Nov 202325105
Dec 20231908
Jan 202415010
Feb 20242065
Mar 202419511
Apr 2024321113
May 2024713
Jun 202413415
Jul 202421518
Aug 202416118
Sep 202434813
Oct 20241054
Nov 202411210
Dec 20241516
Jan 2025864
Feb 2025206113
Mar 20253610740
Apr 2025332687
May 2025302222
Jun 2025331927
Jul 2025433325
Aug 2025858
Back to top
Posted December 14, 2022.
Download PDF
Data/Code
Email
Long-term safety and efficacy of treating symptomatic, partial-thickness rotator cuff tears with fresh, uncultured, unmodified, autologous, adipose-derived regenerative cells isolated at the point of care: 40 months follow-up of a prospective, randomized, controlled, first-in-human clinical trial
Mark Lundeen, Jason L. Hurd, Matthew Hayes, Meredith Hayes, Tiffany R. Facile, John P. Furia, Nicola Maffulli, Christopher Alt, Eckhard U. Alt, Christoph Schmitz, David A. Pearce
medRxiv 2022.12.14.22283447; doi: https://doi.org/10.1101/2022.12.14.22283447
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area